The 429 monoclonal antibody specifically binds to both the long (~110 kDa) transmembrane-spanning form and the truncated (~47 kDa) GPI-linked form of vascular cell adhesion molecule-1 (VCAM-1, CD106). CD106 is constitutively expressed on bone marrow stromal cells, myeloid cells, and splenic dendritic cells. Its expression on endothelial cells is upregulated by inflammatory cytokines and in certain pathologic conditions. CD106 expression has also been detected on apoptotic thymocytes, splenocytes, and lymphoid cell lines. VCAM-1 is a counter-receptor for VLA-4 (α4β1 integrin) and LPAM-1 (α4β7 integrin), and the 429 antibody partially blocks VCAM-1-mediated binding functions. Source of the immunogen was the mouse preadipose cell line PA6.
The antibody was conjugated to BD Horizon BUV661 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome of BD Horizon BUV395 with an Ex Max of 348-nm and an acceptor dye with an Em Max at 661-nm. BD Horizon Brilliant BUV661 can be excited by the ultraviolet laser (355 nm) and detected with a 670/25 filter and a 630 nm LP. Due to cross laser excitation of this dye, there may be significant spillover into channels detecting APC-like emissions (eg, 670/25-nm filter).